Five Star Trader · Free research tool
Five Star Market Map
Discover the stocks inside ETFs and compare their reported weightings.
SMH semiconductor stocks ↓ · DRAM memory stocks ↓ · IBB biotech stocks ↓ · Biotech IPO watchlist ↓
Inside the Index
Explore S&P 500 and Nasdaq-100 ETF holdings. Hover over a slice or tile for its ticker and weight, or select a stock to compare the funds.
Choose your view
Slice and tile areas show fund weights, or company exposure for DRAM. Matching colors identify the same stock across the charts. The gray area is the rest of each fund. These chart legends show only the selected top stocks; open the full list to see every holding.
Discover newer biotech stocks
Biotech IPO Watchlist
Get to know 12 companies that went public between January 2024 and February 2026. Select a ticker or company to read what it does and explore its official updates.
AGMBAgomab Therapeutics
Agomab develops medicines for diseases in which inflammation and scar tissue damage organs. Its programs include treatments for narrowing of the intestine in Crohn’s disease and for idiopathic pulmonary fibrosis, a disease that scars the lungs.
SGPSpyGlass Pharma
SpyGlass develops systems that release medicine inside the eye over an extended period. Its approach combines established drugs with ophthalmic devices and procedures to help manage chronic eye diseases and reduce the burden of frequent treatment.
EIKNEikon Therapeutics
Eikon develops medicines with an initial focus on cancer. It combines biological research with engineering tools to discover drug candidates and is advancing a clinical pipeline that includes programs for melanoma and lung cancer.
MANEVeradermics
Veradermics develops prescription treatments for pattern hair loss in women and men. Its lead program, VDPHL01, is an extended-release oral formulation of minoxidil being evaluated in clinical trials.
AKTSAktis Oncology
Aktis develops targeted radiopharmaceuticals: medicines designed to deliver radioactive treatment to cancer cells. Its research uses small targeting proteins to reach tumors, with the goal of expanding the cancers that can be treated with this approach.
MAZEMaze Therapeutics
Maze uses insights from human genetics to develop oral medicines for kidney and metabolic diseases. Its programs include treatments for APOL1-related kidney disease and phenylketonuria, an inherited disorder that affects how the body processes an amino acid.
SEPNSepterna
Septerna develops oral medicines that act on G protein-coupled receptors, proteins that help cells receive signals. Its drug-discovery platform supports research in hormone disorders, inflammation, immune diseases and metabolic conditions.
UPBUpstream Bio
Upstream Bio develops treatments for severe inflammatory respiratory diseases. Its lead antibody, verekitug, targets the receptor for an inflammatory signal called TSLP. The company is studying it in severe asthma, chronic sinus disease with nasal polyps and COPD.
BCAXBicara Therapeutics
Bicara develops treatments for solid-tumor cancers. Its lead candidate, ficerafusp alfa, is being studied in head-and-neck cancer and other tumors, including in combination with immunotherapy. The company’s approach aims to address both cancer cells and their surrounding environment.
ZBIOZenas BioPharma
Zenas develops therapies for autoimmune diseases, in which the immune system attacks the body’s own tissues. Its pipeline includes antibody and oral treatments intended to control immune activity, with programs spanning several chronic autoimmune conditions.
KYTXKyverna Therapeutics
Kyverna develops CAR-T cell therapies for autoimmune diseases. These treatments modify a patient’s immune cells to target disease-driving cells. Its research includes serious neurological and rheumatological autoimmune conditions.
CGONCG Oncology
CG Oncology develops immunotherapies for bladder cancer. Its lead program, cretostimogene, is designed to attack cancer cells and stimulate an immune response. The company’s goal is to provide treatment options that may help patients preserve their bladder.
Company profiles reviewed October 1, 2026. A selected research watchlist, not a complete IPO list or a list of IBB holdings. The profiles describe drug-development programs, not proof of treatment approval. Review company announcements for trial results, regulatory decisions and financing updates before trading.